The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The archive — 2025
Page 11 of 68 of this archive, newest first.
Nigeria caps liraglutide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What a 35% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Adsorption, and the dose that stayed on the glass
An in-use period is established by a dedicated study on a specific formulation in a specific container at a specific concentration. Borrowing one from a marketed product is…
Independent analysis puts a CPC dulaglutide lot at 96.5%, against 94.8% on the certificate
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
Denmark declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Xi'an export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Delayed emptying explains some of this, and not all of it
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
Asparagine, glycine, and the two residues that decide a shelf life
We describe each pathway in enough chemical detail to explain why it is invisible to the method the trade uses, because that is the part which has practical consequences.
How much of cagrilintide weight loss can any instrument actually attribute?
The compartment called lean mass contains water, glycogen, viscera and skin. Only some of it is the tissue anybody is worried about.
The online reseller trading as Adamant Research Supply closes after 19 years
A proper account of an operation that existed, and of what closing it cost.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
FLOW misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
How a correct calculation becomes a wrong dose
A pharmacist catches most of these in licensed practice. In this market there is no pharmacist, so the checks have to be structural.
Why the fifth week of a semaglutide dose feels different from the first
An accumulation model, drawn from published parameters, with its assumptions stated.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
A supplier suspends shipping to Portugal after 13 consecutive customs detentions
The route did not close because of a rule about peptides.
What a 13% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
Canada caps liraglutide prescribing to 4 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sterility is not a percentage, which is the whole difficulty
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
Why the independent testing market grew a chemistry arm and not a microbiology one
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
The United Kingdom health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The Netherlands declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The named comparison we promised two years ago
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.